JP2025114869A5 - - Google Patents

Info

Publication number
JP2025114869A5
JP2025114869A5 JP2025086115A JP2025086115A JP2025114869A5 JP 2025114869 A5 JP2025114869 A5 JP 2025114869A5 JP 2025086115 A JP2025086115 A JP 2025086115A JP 2025086115 A JP2025086115 A JP 2025086115A JP 2025114869 A5 JP2025114869 A5 JP 2025114869A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
premature infant
administered
pma
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025086115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025114869A (ja
Filing date
Publication date
Priority claimed from JP2020514518A external-priority patent/JP7819893B2/ja
Application filed filed Critical
Publication of JP2025114869A publication Critical patent/JP2025114869A/ja
Publication of JP2025114869A5 publication Critical patent/JP2025114869A5/ja
Pending legal-status Critical Current

Links

JP2025086115A 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物 Pending JP2025114869A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
US62/557,113 2017-09-11
JP2020514518A JP7819893B2 (ja) 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 METHODS AND COMPOSITIONS FOR TREATING CHRONIC PULMONARY DISEASES
JP2023125304A JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023125304A Division JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物

Publications (2)

Publication Number Publication Date
JP2025114869A JP2025114869A (ja) 2025-08-05
JP2025114869A5 true JP2025114869A5 (cg-RX-API-DMAC10.html) 2025-10-20

Family

ID=63794620

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020514518A Active JP7819893B2 (ja) 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物
JP2025086115A Pending JP2025114869A (ja) 2017-09-11 2025-05-23 慢性肺疾患を治療するための方法および組成物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020514518A Active JP7819893B2 (ja) 2017-09-11 2018-09-11 慢性肺疾患を治療するための方法および組成物
JP2023125304A Pending JP2023145646A (ja) 2017-09-11 2023-08-01 慢性肺疾患を治療するための方法および組成物

Country Status (25)

Country Link
US (3) US20190151411A1 (cg-RX-API-DMAC10.html)
EP (3) EP3681602B1 (cg-RX-API-DMAC10.html)
JP (3) JP7819893B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200097679A (cg-RX-API-DMAC10.html)
CN (1) CN111432881A (cg-RX-API-DMAC10.html)
AU (2) AU2018328827B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020004760A2 (cg-RX-API-DMAC10.html)
CA (1) CA3075482A1 (cg-RX-API-DMAC10.html)
CL (1) CL2020000597A1 (cg-RX-API-DMAC10.html)
CO (1) CO2020004244A2 (cg-RX-API-DMAC10.html)
DK (1) DK3681602T3 (cg-RX-API-DMAC10.html)
EA (1) EA202090705A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP20055797A (cg-RX-API-DMAC10.html)
ES (1) ES3075637T3 (cg-RX-API-DMAC10.html)
IL (1) IL273174B2 (cg-RX-API-DMAC10.html)
LT (1) LT3681602T (cg-RX-API-DMAC10.html)
MX (1) MX421623B (cg-RX-API-DMAC10.html)
MY (1) MY204825A (cg-RX-API-DMAC10.html)
PE (1) PE20201166A1 (cg-RX-API-DMAC10.html)
PH (1) PH12020500489A1 (cg-RX-API-DMAC10.html)
PT (1) PT3681602T (cg-RX-API-DMAC10.html)
SG (1) SG11202002088TA (cg-RX-API-DMAC10.html)
UA (1) UA128690C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019051474A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202001568B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd
KR20230113287A (ko) * 2020-10-19 2023-07-28 오크 힐 바이오 리미티드 신생아에 사용하기에 적합한 조성물
CA3248280A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited POLYTHERAPY FOR PREMATURE INFANTS
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
EP0639981A4 (en) 1992-05-08 1995-06-28 Univ Jefferson ANALOGS OF THE IGF FACTOR (01/18/94).
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
EP0956041A1 (en) 1996-09-16 1999-11-17 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US20020028764A1 (en) 2000-09-04 2002-03-07 Aarhus Amt. Treatment of acute and chronic liver disease
CA2429615C (en) 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
WO2004113382A1 (en) 2003-06-13 2004-12-29 Insmed, Inc. Recombinant igf expression systems
CA2899824A1 (en) 2004-12-24 2006-06-29 Insmed, Inc. Purified rhigf-i/rhigfbp-3 complexes and their method of manufacture
WO2008130315A1 (en) * 2007-04-18 2008-10-30 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
RU2558821C2 (ru) 2009-11-17 2015-08-10 Ипсен Фарма С.А.С. ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ КОМБИНАЦИИ hGH И rhIGF-1
US9168289B2 (en) 2011-02-01 2015-10-27 Mor Research Applications Ltd. Method of treatment of small for gestational age infants under two years of age
CA2897062A1 (en) 2013-01-15 2014-07-24 Teva Pharmaceutical Industries Ltd. Lyophilization process
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
EP3681602B1 (en) 2017-09-11 2026-04-15 Oak Hill Bio Limited Compositions for reducing the incidence of bpd

Similar Documents

Publication Publication Date Title
US20080248999A1 (en) Amylin formulations
EP0921812B2 (en) Insulin preparations containing a halogenide
JP2023550203A5 (cg-RX-API-DMAC10.html)
JP2813017B2 (ja) 癌療法の副作用の減少方法
JP2961045B2 (ja) 腸管粘膜増強促進剤
WO2003094951A1 (en) Soluble formulations comprising insulin aspart and insulin detemir
ZA200600846B (en) Novel insulin derivatives
CN106232141A (zh) 针对由给予类固醇诱发的生长不足的药物
CN118234504A (zh) 治疗剂的口服递送
JP2004501870A (ja) ガン患者における化学療法の副作用を軽減させる方法
JPS63303930A (ja) インシユリンおよびインシユリン誘導体の混合結晶
JP2020533344A5 (cg-RX-API-DMAC10.html)
US5198422A (en) Stabilized somatotropin for parenteral administration
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
JP2024506145A5 (cg-RX-API-DMAC10.html)
GB2244918A (en) Pharmaceutical compositions comprising somatosatin and cholanic acid derivatives
US4963529A (en) Stable growth hormone releasing factor preparation
Hashizume et al. Prader‐Willi Syndrome with del (15)(q1l, q13) Associated with Hepatoblastoma
US6153581A (en) Drug for recovering renal function
AU650050B2 (en) Product and use of it for the treatment of catabolic states comprising authentic IGF-1 and hypocaloric amount of nutritients
JP2025502349A (ja) Igf-1/igfbpの酸化を低減するための組成物および方法
JP4023863B2 (ja) Il−6を含む血清尿酸値低下剤
JP5034944B2 (ja) インターフェロン作用物質の活性増強剤
US3102844A (en) Oral iron-glucosamine hematinic composition and therapy
US20250361201A1 (en) N-[8-(2-hydroxybenzoyl)amino]potassium octanoate crystal polymorph, and preparation method therefor and use thereof